RecruitingNot ApplicableNCT06150950

REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

RCT of the Effects of Cardiac reHABilitation (REHAB) Among Patients With Fontan Failure


Sponsor

Stanford University

Enrollment

50 participants

Start Date

May 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to compare the impact of cardiac rehabilitation on Fontan failure patients' exertional tolerance, frailty, and quality of life. 1. Among patients with Fontan failure, will cardiac rehabilitation increase average daily steps compared to usual care? 2. Among patients with Fontan failure, will cardiac rehabilitation improve exertional tolerance (as measured by cardiopulmonary exercise testing), frailty, and self-reported quality of life metrics compared to usual care?


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Fontan failure, defined as history of a Fontan procedure and at least one of the following: systemic ventricular EF \<50% (by echocardiography, cardiac magnetic resonance imaging, or computer tomography), protein losing enteropathy, plastic bronchitis, chronic loop diuretics prescribed by ACHD Cardiologist, and/or peak VO2 \< 50% predicted (by FRIEND equation)
  • Age \>= 18 years old

Exclusion Criteria7

  • Inotrope-dependence
  • Symptomatic, uncontrolled arrhythmias
  • Pregnancy
  • Contraindication to cardiac rehab or already enrolled in cardiac rehabilitation
  • Inability to comply with the protocol
  • Recent (\<3 months) planned Fontan pathway percutaneous or surgical intervention
  • Resting hypoxemia with baseline oxygen saturation \<80%

Interventions

BEHAVIORALCardiac rehabilitation

Cardiac rehabilitation is a multifaceted, comprehensive therapeutic intervention of personalized, supervised exercise training that is beneficial and well-studied among patients with non-ACHD heart failure and has consistently been shown to improve QOL. Unfortunately, cardiac rehabilitation has been underutilized with an overall participation \<50% of eligible patients despite international guidelines advocating for more consistent deployment of cardiac rehabilitation. A major a barrier to cardiac rehabilitation is access, as CMS-mandates a physician be within 3 minutes of the rehabilitation facility to assure insurance reimbursement. This mandate limits isolated, outpatient cardiac rehabilitation programs, especially in rural communities.

OTHERUsual care

For participants randomized to the usual care (no cardiac rehabilitation group), cardiac rehabilitation will not be initiated between randomization and for up to 16 weeks following randomization. The study protocol controls only referral to cardiac rehabilitation. All other aspects of the cardiac care, such as titration of guideline directed medical therapy will be at the discretion of clinicians.


Locations(2)

Stanford University

Stanford, California, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06150950


Related Trials